Friday, June 2, 2017

BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)

* European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)